Verge Genomics

Verge Genomics

- Model ConVERGE - Drug Discovery Platform

0

The breadth and depth of our pipeline demonstrates the power of the ConVERGEMplatform. All pipeline programs have been discovered and developed on our proprietary platform.

Details

The ConVERGETM platform addresses diseases where biology is the bottleneck. Our programs target therapeutic areas where:

  • Multi-factorial components (genetics, environment, and time) intersect in complex ways to culminate in overt disease
  • Animal or cell models do not predict human efficacy
  • There is high unmet need, no disease-modifying therapies, or significant shortcomings with existing treatment paradigms

From novel target to clinical candidate on one pla...

From novel target to clinical candidate on one platform.
We are the first AI-enabled drug discovery company to discover a novel target and develop it into a clinical candidate entirely in-house. Most AI-enabled companies make new drugs against old targets, or old drugs against new targets. We discovered a new target from our platform and developed our own proprietary clinical compound internally 'soup-to-nuts.”

Approach

Our end-to-end ConVERGETM discovery platform is a closed-loop machine learning system combining industry-leading proprietary human genomics with advanced computational tools to predict new drugs with a higher probability of clinical success.

Our end-to-end ConVERGETM discovery platform is a closed-loop machine learning system combining industry-leading proprietary human genomics with advanced computational tools to predict new drugs with a higher probability of clinical success.

Customer reviews

No reviews were found for Verge - Model ConVERGE - Drug Discovery Platform. Be the first to review!